RxDoctor Payments Data

Jonathan Perley, MD

Urology · Lakewood, CANPI 1326017831

Payments from drug & device makers

$34,561in general payments, 2019–2025

Across 504 payments — averaging $68.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$13K
  • Medtronic$5K
  • Boston Scientific$3K
  • Coloplast$3K
  • Neotract Inc.$2K
  • Axonics, Inc.$1K
  • plus $8K from 44 others
$12,300in research payments, 2019–2025

Across 2 payments — averaging $6150.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Coloplast$12K

What the payments were for

  • Consulting fees$2,8338%
  • Speaking & faculty fees$7,50922%
  • Grants$1,0003%
  • Travel & lodging$1,1303%
  • Food & beverage$19,51756%
  • Education$2,5727%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,561 in reported general payments places this provider in the 85th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$354,077
Medicare patients
316
Services billed
4,728

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide11$154,089
MyrbetriqMirabegron163$83,791
Tolterodine Tartrate ErTolterodine Tartrate421$37,775
GemtesaVibegron46$36,252
Solifenacin Succinate75$6,588
Estradiol76$5,641
Alfuzosin Hcl ErAlfuzosin Hcl325$3,612
Tamsulosin Hcl162$1,808
CeftriaxoneCeftriaxone Sodium40$1,101
Oxybutynin Chloride ErOxybutynin Chloride13$830
Ciprofloxacin Hcl195$346
Sildenafil Citrate49$247
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst14$237
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim32$125
Finasteride18$91

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$418$237,879174 claims
Sumitomo Pharma America, Inc.Gemtesa$357$36,25246 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,324 urology providers in California.

Other urology in Lakewood

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →